Saturday 7 November 2026 Export STOK’s income statement to Excel — free account

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.

Revenue: +5.86%
EPS: −65.7%
Free cash flow: −114.9%

Quarter to September 2026, against a year earlier

26.54 0.47 +1.80%

Follow STOK

Alert me

Market cap: $1.7B
P/E: 0.0×
Fwd P/E: −6.7×
Dividend yield: —
F-score: 5/9
Altman Z: 16.42
Beneish M: 0.76
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 6.51

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	8	—	—	9	1	1	2	1	4	—	2	1

Insider Ownership 21.40%

Capital & Financial Ratios $m

Size

Market Cap 1,710.00

Revenue ttm 28.21

Net income ttm (243.20)

Free cash flow ttm (215.72)

Net debt Q (319.19)

Valuation

P/E 0.00

Forward P/E (6.67)

Price / sales 64.12

Forward P/S Powerpack

Price / FCF 0.00

Price / book 5.13

Financial health

Current ratio Q 7.24

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q +5.86%

Operating income growth Q −79.42%

EPS, this year −3,201.67%

EPS, next year A −3.18%

Revenue, next year A −81.17%

EPS, past 5 yrs —

EPS, next 5 yrs A −24.20%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 84.06%

10-year low 10-year high

P/B against its own 10 years 76.68%

10-year low 10-year high

EV/Sales against its own 10 years 85.49%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	201	217	285	319
Receivables	0	2	8	10
Inventory	—	—	—	—
Other	3	2	4	8
	215	233	306	354

	2023	2024	2025	Q'26
Payables	2	2	5	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	31	40	58	49

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	145.89%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	4.26%	24.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.88 Actual −1.08

−1.15 −1.04 −0.92 −0.81 −0.70

Q4 FY25 Miss −0.22

Q1 FY26 Beat +0.01

Q2 FY26 Miss −0.11

Q3 FY26 Miss −0.20

Q4 FY26 — Mar 15

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−0.75	−0.97	Miss by 0.22
Q1 FY26	−0.80	−0.79	Beat by 0.01
Q2 FY26	−0.82	−0.93	Miss by 0.11
Q3 FY26	−0.88	−1.08	Miss by 0.20
Q4 FY26	−1.10	—	Reports 15 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.79)	(0.93)	(1.08)	—	—
’25	1.90	(0.40)	(0.65)	(0.97)	(0.12)
’24	(0.57)	(0.46)	(0.47)	(0.18)	(1.65)
’23	(0.53)	(0.69)	(0.55)	(0.60)	(2.38)
’22	(0.66)	(0.63)	(0.66)	(0.65)	(2.60)
’21	(0.46)	(0.60)	(0.61)	(0.66)	(2.34)
’20	(0.34)	(0.39)	(0.41)	(0.42)	(1.56)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	9	11	—	—
’25	159	14	11	1	184
’24	4	5	5	23	37
’23	5	(2)	3	3	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(61)	(57)	(63)	—	—
’25	132	(25)	(30)	(30)	46
’24	(25)	(17)	(22)	(23)	(87)
’23	(21)	(22)	(17)	(21)	(81)
’22	32	(20)	(22)	(22)	(32)
’21	(20)	(16)	(15)	(16)	(67)
’20	(11)	(10)	(11)	(11)	(42)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(61)	(59)	(66)	—	—
’25	132	(26)	(30)	(31)	45
’24	(25)	(18)	(22)	(23)	(87)
’23	(22)	(23)	(18)	(21)	(83)
’22	32	(21)	(24)	(23)	(36)
’21	(20)	(16)	(15)	(16)	(68)
’20	(11)	(10)	(11)	(11)	(43)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	12	9	37	184	28		+145.9%	35	51	136	(9.6%)
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack Stoke Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to shrink 9.6% a year to 2028 — slower than the 145.9% of the last 3 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	(6)	(13)	(32)	(52)	(86)	(101)	(105)	(89)	(7)	(243)		+2.7%
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	(814.73)	(1,192.47)	(243.42)	(3.73)	(862.07)		(3.7) pt
	Net income	—	0	(13)	(32)	(52)	(86)	(101)	(105)	(89)	(7)	(243)		n/m
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.32	0.20	0.68	3.11	0.41		n/m
	Earnings	—	(0.17)	(17.65)	(1.80)	(1.56)	(2.34)	(2.60)	(2.38)	(1.65)	(0.12)	(3.80)		(4.3%)
	Cash flow	—	(0.16)	(15.46)	(1.73)	(1.26)	(1.82)	(0.82)	(1.84)	(1.61)	0.77	(3.08)		n/m
	Capex	—	0.00	(1.30)	(0.09)	(0.03)	(0.03)	(0.10)	(0.04)	0.00	(0.01)	(0.08)		n/m
	Free cash flow	—	(0.16)	(16.76)	(1.82)	(1.29)	(1.85)	(0.92)	(1.88)	(1.61)	0.76	(3.16)		n/m
	Book value	—	(0.04)	148.13	12.49	8.54	5.93	4.75	3.63	4.24	5.95	5.16		n/m
	Shares, m	—	33	1	18	33	37	39	44	54	59	64		+7.7%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	—	—	28.50	29.36	16.30	10.19	64.12		21.1
	P/B	—	—	—	—	—	—	1.91	1.62	2.60	5.33	5.13		2.9
	EV/Sales	—	—	—	—	—	—	9.99	6.43	10.36	8.65	52.81		8.9
	EV/FCF	—	—	—	—	—	—	(3.46)	(0.68)	(4.35)	35.51	(6.91)		6.8
Cash, $m
Cash, $m	Operating cash flow	—	(5)	(11)	(31)	(42)	(67)	(32)	(81)	(87)	46	(210)		n/m
	Capex	—	0	(1)	(2)	(1)	(1)	(4)	(2)	0	(1)	(5)		+24.9%
	Free cash flow	—	(5)	(12)	(33)	(43)	(68)	(36)	(83)	(87)	45	(216)		n/m
Balance, $m
Balance, $m	Working capital	—	(2)	104	222	283	212	213	185	193	248	305		n/m
	Net debt	—	1	(105)	(222)	(287)	(220)	(230)	(201)	(217)	(285)	(319)		n/m
	Shareholders’ equity	—	(1)	105	224	286	218	185	160	229	352	353		n/m
Returns, %
Returns, %	ROA	—	(10.11)	(23.29)	(19.22)	(19.84)	(31.97)	(40.84)	(43.23)	(35.60)	(2.00)	(63.42)		+8.1 pt
	ROIC	—	0.00	0.00	(1,139.44)	0.00	0.00	0.00	0.00	(525.92)	(19.12)	(482.02)		(19.1) pt
	ROE	—	(10.71)	(24.13)	(19.62)	(20.47)	(34.06)	(50.20)	(60.80)	(45.80)	(2.37)	(73.62)		+8.3 pt
People
People	Employees	—	—	44	56	79	102	117	110	128	170	—		+21.3%
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.11	0.08	0.29	1.08	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MAZE Maze Therapeutics, Inc.	$1.8B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+10.14% (above 0%: growing)	n/m	+123.88% (above 0%: growing)	35.31%	(44.97%)	Compare
STOK Stoke Therapeutics, Inc.	$1.7B	— (loss-making)	— (loss-making)	+5.86% (above 0%: growing)	n/m	−114.89% (below 0%: shrinking)	100.00%	(686.94%)
AGIO Agios Pharmaceuticals, Inc.	$1.7B	— (loss-making)	— (loss-making)	+330.01% (above 0%: growing)	n/m	+32.64% (above 0%: growing)	95.44%	(139.32%)	Compare
ZBIO Zenas BioPharma, Inc.	$1.7B	— (loss-making)	— (loss-making)	—	n/m	−41.00% (below 0%: shrinking)	100.00%	(1,034.09%)	Compare
LYCA Lycia Therapeutics Inc.	$1.7B	—	—	—	—	—	—	—	Compare
NRIX Nurix Therapeutics, Inc.	$1.6B	6.1×	5.5×	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ABSI Absci Corporation	$1.6B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
GENB Generate Biomedicines, Inc.	$1.6B	— (loss-making)	— (loss-making)	—	n/m	−224.24% (below 0%: shrinking)	100.00%	(1,134.21%)	Compare
Median of peers	$1.7B	—	—	+170.08%	—	+32.64%	100.00%	(139.32%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Directors and executive officers, together 9.60%

Entities affiliated with FMR LLC 9.00%

Entities affiliated with RTW Investments, L.P. 8.50%

Entities affiliated with Lynx1 Capital Management LP 8.30%

Entities affiliated with Redmile Group, LLC 7.00%

BlackRock, Inc. 6.00%

Entities affiliated with Morgan Stanley & Co. 5.50%

Entities affiliated with Baker Bros. Advisors LP 5.40%

The Toronto-Dominion Bank 5.10%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Stoke Therapeutics, Inc. (STOK) Latest News

30 Oct

Impact 3 · 10:29 AM · The Motley Fool transcript

Stoke (STOK) Q3 2026 Earnings Call Transcript

Impact 3 · 8:30 AM · Moby transcript

Stoke Therapeutics, Inc. Q3 2026 Earnings Call Summary

29 Oct

Impact 4 · 10:14 PM · MarketBeat

Stoke Therapeutics Q3 Earnings Call Highlights

Impact 4 · 4:01 PM · Business Wire

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Impact 3 · 6:05 PM · Zacks

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

22 Oct

Impact 4 · 8:00 AM · Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

12 Oct

Impact 4 · 8:00 AM · Business Wire

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

9 Oct

Impact 4 · 7:09 PM · Simply Wall St.

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

6 Oct

Impact 4 · 8:00 AM · Business Wire

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

5 Oct

Impact 4 · 7:00 AM · Business Wire

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

23 Sep

Impact 3 · 4:01 PM · Business Wire

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

3 Sep

Impact 4 · 7:30 PM

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

1 Sep

Impact 4 · 7:30 AM

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Impact 4 · 7:30 AM · GlobeNewswire

21 Aug

Impact 3 · 5:53 AM · InvestorsHub

Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating

17 Aug

Impact 4 · 8:01 PM · MarketBeat

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

10 Aug

Impact 3 · 9:58 PM · The Motley Fool transcript

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

7 Aug

Impact 3 · 2:14 AM

What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?

4 Aug

Impact 3 · 8:30 AM · Moby transcript

Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary

Impact 3 · 1:07 AM

Stoke Therapeutics Inc (STOK) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...

3 Aug

Impact 3 · 6:03 PM · MarketBeat transcript

Stoke Therapeutics Q2 Earnings Call Highlights

Impact 3 · 5:10 PM

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Impact 3 · 4:01 PM

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

14 Jul

Impact 3 · 10:04 AM

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study

30 Jun

Impact 4 · 8:00 AM

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

1 Jun

Impact 3 · 4:02 AM · Insider Monkey

Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates

11 May

Impact 4 · 9:33 AM · Simply Wall St.

Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results

9 May

Impact 3 · 12:07 AM · MarketBeat

Stoke Therapeutics Q1 Earnings Call Highlights

7 May

Impact 3 · 7:05 PM · Zacks

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Impact 3 · 4:01 PM · Business Wire

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Stoke Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Stoke Therapeutics, Inc. (STOK) Latest News

30 Oct

29 Oct

22 Oct

12 Oct

9 Oct

6 Oct

5 Oct

23 Sep

3 Sep

1 Sep

21 Aug

17 Aug

10 Aug

7 Aug

4 Aug

3 Aug

14 Jul

30 Jun

1 Jun

11 May

9 May

7 May

Stockrow Weekly